Humacyte (HUMA) Total Non-Current Liabilities (2020 - 2026)

Humacyte (HUMA) has reported Total Non-Current Liabilities for 7 consecutive years, with $91.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 15.61% year-over-year to $91.2 million in Q2 2026; TTM through Jun 2026 was $91.2 million, a 15.61% decrease from a year earlier, with the FY2025 full-year figure at $93.9 million, down 21.5% from the prior year.
• Total Non-Current Liabilities was $91.2 million for Q2 2026 at Humacyte, up from $88.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $119.6 million in Q4 2024 and troughed at $59.0 million in Q1 2023.
• A 5-year average of $82.9 million and a median of $82.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The widest YoY moves for Total Non-Current Liabilities: up 2558.58% in 2022, down 72.44% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $59.5 million in 2022, then advanced by 29.05% to $76.8 million in 2023, then surged by 55.78% to $119.6 million in 2024, then decreased by 21.5% to $93.9 million in 2025, then declined by 2.87% to $91.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $91.2 million (Q2 2026), $88.1 million (Q1 2026), and $93.9 million (Q4 2025), per Business Quant data.